JB Chemicals & Pharmaceuticals Ltd - 506943 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Submission of Information of loss of share certificate under Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 JB Chemicals & Pharmaceuticals Ltd - 506943 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper advertisement for Postal Ballot J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - 1) Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 (2) Disclosure Under Code Of Practices And Procedure For Disclosure Of UPSI
This is to inform you that National Pharmaceuticals Pricing Authority, vide order dated July 1, 2021, in exercise of its powers under Para 19 of Drugs (Prices Control) Order, 2013 has, in public interest, notified one-time price increase of 50% from the present ceiling price of 3 dosage forms of Ranitidine. The Company markets Ranitidine under the 'Rantac' brand name in India. JB Chemicals & Pharmaceuticals Ltd - 506943 - Postal Ballot Notice
Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the Securities and Exchange Board of India circular bearing reference no. CIR/CFD/CMD/4/2015 dated September 9, 2015 JB Chemicals & Pharmaceuticals Ltd - 506943 - Closure of Trading Window
Closure of Trading Window
Exclusive: KKR-controlled drug maker JBCPL evaluating acquistion of select brands, mid-sized firm
KKR's deep pockets and expertise is expected to help JBCPL to expand quickly using both organic and inorganic options. KKR bought a controlling stake in the Mumbai-based family-owned drug maker JBCPL a year ago for Rs 3,100 crore. JB Chemicals & Pharmaceuticals Ltd - 506943 - Newspaper Cutting Of Extract Of Consolidated Financial Results For Quarter And Year Ended March 31, 2021.
Newspaper cutting of extract of consolidated financial results for quarter and year ended March 31, 2021.
Earnings Call for Q4FY21 of J B Chemicals & Pharmaceuticals
Conference Call with J B Chemicals & Pharmaceuticals Management and Analysts on Q4FY21 Performance and Outlook. Listen to the full earnings transcript.
JB Chemicals & Pharmaceuticals Q4 net profit jumps two-fold to Rs 101 cr
Drug firm JB Chemicals & Pharmaceuticals on Monday reported a two-fold jump in consolidated net profit to Rs 100.81 crore for the quarter ended March 2021 on account of robust sales. The company had posted a net profit of Rs 50.07 crore for the corresponding period of the previous fiscal year, JB Chemicals & Pharmaceuticals said in a regulatory filing. Consolidated revenue from operations stood at Rs 528 crore for the quarter under consideration. It was Rs 444 crore for the same period a year ago, it added. For the full fiscal 2020-21, the net profit of the company was Rs 449 crore as against Rs 272 crore for the previous year, the filing said. Revenue from operations for the fiscal year ended March 2021 stood at Rs 2,043 crore. It was Rs 1,775 crore in FY20. The board of directors has recommended a final dividend of Rs 8 per equity share of face value of Rs 2 for the financial year 2020-21, it added. "Our financial performance for FY21 has been encouraging in one of the most .